Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to FDA

Monthly Prescribing Reference (MPR)

FDA Allows Certified Retail Pharmacies to Dispense Mifepristone

Clinical Pharmacology January 30th 2023

Specialty Pharmacy Continuum

FDA Approves Adstiladrin, First Gene Therapy for Bladder Cancer

Clinical Pharmacology January 30th 2023

Infectious Disease Special Edition (IDSE)

CDC, FDA: Risk for Stroke in Seniors Following Updated COVID-19 Vaccine ‘Very Unlikely’

Allergy & Immunology January 24th 2023


“Tentative Approval”: Understanding the FDA Ruling on Once-Nightly Sodium Oxybate

Internal Medicine January 18th 2023

Monthly Prescribing Reference (MPR)

AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market

Hematology January 17th 2023

MedPage Today

Crystal Ball Cloudy for PI3K Inhibitors’ Future in Hematology

Hematology January 9th 2023

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form